Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GHB Effects on Naloxone-Precipitated Opioid Withdrawal
NCT00000193Phase 2Withdrawn
- Sponsor
- Yale University
- Start
- Jan 1993
- Primary completion
- Jan 1998
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of sodium oxybate in opioid withdrawal (3 arms), sponsored by Yale University. Primary endpoints: Behavioral and subjective measures of naloxone-precipitated withdrawal and Physiological and neuroendocrine measures of naloxone-precipitated withdrawal. Planned start Jan 1993; status: withdrawn.
02
Drugs
sodium oxybate
03
Conditions
opioid withdrawal
Beyond the preview
Go deeper on NCT00000193.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00000193.